GenMark Dx Q1 Revenues Down 29 Percent, Still Beat Analyst Estimates | GenomeWeb

NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Tuesday that its revenues in the first quarter were down 29 percent year over year but the firm still beat the consensus analyst estimate on the top and bottom lines.

The company said that for the three months ended March 31, revenues totaled $7.9 million, compared to $11.1 million in the year-ago quarter, and easily surpassing the average analyst estimate of $6.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.